banner

Brightcove Shares Nosedive on Weak 2013 Guidance

Brightcove (BCOV)

Coming up on its one-year anniversary of being a public entity, shares of Brightcove, Inc. (NASDAQ: BCOV) printed all-time lows after delivering its fourth-quarter and full 2012 year earnings and a weak outlook for 2013.

The provider of cloud-based video streaming services reported total revenue for the fourth quarter of 2012 of $24.3 million, an increase of 31 percent compared to $18.5 million for the fourth quarter of 2011. Gross profit for the fourth quarter of 2012 was $16.7 million, compared to $12.9 million for the fourth quarter of 2011. Excluding items, adjusted net loss totaled $1.5 million, or 5 cents per share, compared to a net loss of $2.7 million, or 53 cents per share in the year prior quarter.

Revenue and net loss actually beat the expectations of Wall Street analysts, whom were calling for revenue of $23.2 million and a net loss of 7 cents per share.



What wiped the luster off the stock was the company’s 2013 guidance. Brightcove said that it expects an adjusted net loss in the range of 18 cent to 25 cents per share and revenue between $102 million and $105 million.

Analysts were only expecting a loss of 13 cents per share and revenue of $106 million.

Keeping things upbeat, Brightcove chairman and chief executive* Jeremy Allaire said in a corporate statement, “Brightcove ended 2012 on a strong note, with our fourth quarter results once again exceeding our revenue and profitability guidance.” Why the asterisk, you may ask? Because Brightcove also announced that Allaire has resigned as CEO and that Chief Operating Officer David Mendels is assuming the Allaire’s position on March 31. At that time, Allaire will become the Executive Chairman of the Board.

Meanwhile, Accel Partners’ James Breyer resigned from the Brightcove board, the company said today.

For the complete 2012 year, total revenue for Brightcove was $88.0 million, an increase of 38 percent compared to $63.6 million for 2011. Gross profit was $60.6 million for 2012, compared to $43.3 million for 2011. Non-GAAP gross profit was $61.2 million for 2012, representing a year-over-year increase of 41 percent. Excluding items, adjusted net loss for 2012 was $8.3 million, or 34 cents per share, compared to an adjusted net loss of $13.4 million, or $2.74 per share in 2011.

Share of BCOV debuted February 17 at $14.50 per share. After a run to highs of $25.43 at the end of March, shares have been steadily bleeding-out value since, closing Thursday at $8.42. Shares plunged with the guidance today, dropping to close down by 27.4 percent at $6.11 after establishing a new record low at $5.97.

Brightcove (BCOV) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

Dow Not Tired of Making New Record Highs

Dow Not Tired of Making New Record Highs(0)

The Dow Jones Industrials will have to wait till at least next week to mount the lofty heights of 16,000 points, but both the Dow and the S&P did end the day at record highs. The Dow Jones Industrials was up 85.48 points from yesterday”s all-time high, to close at 15,961.70 The S&P 500 index

read more
banner

Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.